Comparing the effectiveness of Hepa-Mertz mono therapy versus rifaximin in patients presenting with hepatic encephalopathy

被引：0
|
作者：
Doyle, J. B. M. [1 ]
McDougall, N. I. [1 ]
Cash, W. J. [1 ]
机构：
[1] Royal Victoria Hosp, Liver Unit, Belfast BT12 6BA, Antrim, North Ireland
来源：
IRISH JOURNAL OF MEDICAL SCIENCE | 2015年 / 184卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
32(14S161)
引用
收藏
页码：S86 / S86
页数：1
相关论文
共 48 条
  • [1] Cost Effectiveness of Rifaximin Treatment in Patients with Hepatic Encephalopathy
    Jesudian, Arun B.
    Ahmed, Maliha
    Bozkaya, Duygu
    Migliaccio-Walle, Kristen
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (06): : 750 - 757
  • [2] Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy
    Neff, G. W.
    Kemmer, N.
    Zacharias, V. C.
    Kaiser, T.
    Duncan, C.
    McHenry, R.
    Jonas, M.
    Novick, D.
    Williamson, C.
    Hess, K.
    Thomas, M.
    Buell, J.
    TRANSPLANTATION PROCEEDINGS, 2006, 38 (10) : 3552 - 3555
  • [3] Cost-effectiveness of rifaximin treatment in patients with hepatic encephalopathy
    Bozkaya, Duygu
    Barrett, Andrew C.
    Migliaccio-Walle, Kristen
    HEPATOLOGY, 2014, 60 : 389A - 390A
  • [4] Impact of Rifaximin Monotherapy Versus Rifaximin and Lactulose Combination Therapy on Quality of Life in Patients With a History of Overt Hepatic Encephalopathy (OHE)
    Sanyal, Arun J.
    Heimanson, Zeev
    Israel, Robert
    Mullen, Kevin D.
    Flamm, Steven L.
    HEPATOLOGY, 2017, 66 : 268A - 268A
  • [5] Mean Blood Ammonia Level After Treatment With Rifaximin Versus Neomycin In Chronic Liver Disease Patients Presenting With Hepatic Encephalopathy
    Mumtaz, Sami Ullah
    Iqtadar, Somia
    Niaz, Zafar
    Komal, Tayyeba
    Abaidullah, Sajid
    ANNALS OF KING EDWARD MEDICAL UNIVERSITY LAHORE PAKISTAN, 2019, 25 (01): : 37 - 40
  • [6] Evaluation of the cost-effectiveness of rifaximin-α for the management of patients with hepatic encephalopathy in the United Kingdom
    Berni, Ellen
    Murphy, Daniel
    Whitehouse, James
    Conway, Pete
    di Maggio, Paola
    Currie, Craig J.
    Poole, Chris
    CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (11) : 2001 - 2008
  • [7] AN EVALUATION OF REGULATION OF THE EFFECTIVENESS OF RIFAXIMIN IN PATIENTS OF LONG-LASTING LIVER ILLNESS GIVING BY HEPATIC ENCEPHALOPATHY
    Siddique, Ali
    Ul Islam, Reehan
    Sajjad, Ambrina
    INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 6 (04): : 8234 - 8238
  • [8] IMPACT OF UPDATED MORTALITY ESTIMATES ON THE COST-EFFECTIVENESS OF RIFAXIMIN FOR THE TREATMENT OF PATIENTS WITH OVERT HEPATIC ENCEPHALOPATHY
    Bhattacharyya, S.
    John, D.
    Thomas, A.
    Soni, P.
    Jesudian, A. B.
    Dashputre, A. A.
    Joseph, G.
    VALUE IN HEALTH, 2023, 26 (06) : S101 - S101
  • [9] Efficacy and Safety of Rifaximin Versus Placebo or Other Active Drugs in Critical ill Patients With Hepatic Encephalopathy
    Han, Xianghui
    Luo, Zhanyang
    Wang, Wenyi
    Zheng, Peiyong
    Li, Tian
    Mei, Zubing
    Wang, Jianyi
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [10] Emergency Department Utilization in Patients With Hepatic Encephalopathy (HE) Treated With Rifaximin (± Lactulose) versus Lactulose Alone
    Volk, Michael
    Burne, Rebecca
    Guerin, Annie
    Shi, Sherry
    Joseph, George
    Heimanson, Zeev
    Ahmad, Maliha
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S539 - S539
12345